0RPS Stock Chart & Stats
kr215.00
-kr9.20(-4.72%)
At close: 4:00 PM EST
kr215.00
-kr9.20(-4.72%)
Day’s Range― - ―
52-Week Rangekr179.60 - kr264.50
Previous CloseN/A
Volume354.00
Average Volume (3M)12.72K
Market Cap
kr37.99B
Enterprise Valuekr50.31K
Total Cash (Recent Filing)kr92.70M
Total Debt (Recent Filing)kr1.46B
Price to Earnings (P/E)40.7
Beta1.02
Next Earnings
Nov 04, 2026EPS Estimate
1.99Next Dividend Ex-DateN/A
Dividend Yield0.84%
Share Statistics
EPS (TTM)0.56
Shares Outstanding75,424,480
10 Day Avg. Volume1,549
30 Day Avg. Volume12,721
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.74
Price to Sales (P/S)1.29
P/FCF Ratio16.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.65
Revenue Forecast (FY)kr2.59B
Bulls Say, Bears Say
Bulls Say
Organic Growth And Margin ExpansionDouble-digit organic growth across the group, combined with sequential margin improvement, indicates strengthening demand and operating execution. If sustained, this combination can increase earnings capacity, support reinvestment in the clinic and diagnostics networks, and improve resilience over the next several quarters.
Diagnostics Scale And Operational LeverageThe diagnostics network is benefiting from rising test volumes and improving profitability, suggesting that scale and network density are translating into operational leverage. A larger testing base can strengthen institutional relationships, support capacity utilization, and provide a durable earnings contribution.
Improving Cash Generation And LeverageStronger operating cash flow and positive free cash flow improve Medicover’s ability to fund expansion and service debt internally. The reduction in leverage below 3x also increases financial flexibility, giving management more capacity to pursue growth while gradually strengthening the balance sheet.
Bears Say
Elevated Balance-sheet LeverageLeverage remains elevated relative to a more conservative balance sheet, which can constrain capital allocation and increase sensitivity to weaker demand, higher financing costs, or slower cash conversion. Although leverage is improving, the debt burden remains a durable financial risk over the medium term.
Thin Net Profitability And Cash ConversionLow net margins leave less protection against cost inflation, pricing pressure, or unfavorable business mix. Meanwhile, cash flow converting at only about half of net income suggests working capital or capital spending absorbs meaningful profits, limiting the cash available for debt reduction and expansion.
India Expansion Remains Margin DilutiveIndia is producing strong growth but newly opened hospitals are still loss-making, creating a near-term drag on consolidated margins and returns. The expansion can become a long-term asset if utilization improves, but continued ramp-up requires capital and execution before it contributes positively.
Medicover AB News
0RPS FAQ
What was Medicover AB’s price range in the past 12 months?
Medicover AB lowest share price was kr179.60 and its highest was kr264.50 in the past 12 months.
What is Medicover AB’s market cap?
Medicover AB’s market cap is kr37.99B.
When is Medicover AB’s upcoming earnings report date?
Medicover AB’s upcoming earnings report date is Nov 04, 2026 which is in 45 days.
How were Medicover AB’s earnings last quarter?
Medicover AB released its earnings results on Jul 22, 2026. The company reported kr1.818 earnings per share for the quarter, missing the consensus estimate of kr1.863 by -kr0.045.
Is Medicover AB overvalued?
According to Wall Street analysts Medicover AB’s price is currently Overvalued.
Does Medicover AB pay dividends?
Medicover AB pays a Annually dividend of kr2.175 which represents an annual dividend yield of 0.84%. See more information on Medicover AB dividends here
What is Medicover AB’s EPS estimate?
Medicover AB’s EPS estimate is 1.99.
How many shares outstanding does Medicover AB have?
Medicover AB has 75,424,480 shares outstanding.
What happened to Medicover AB’s price movement after its last earnings report?
Medicover AB reported an EPS of kr1.818 in its last earnings report, missing expectations of kr1.863. Following the earnings report the stock price went up 2.955%.
Which hedge fund is a major shareholder of Medicover AB?
Currently, no hedge funds are holding shares in GB:0RPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicover AB
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.